Work together to improve the diagnosis rate of rare diseases in the central nervous system
SHANGHAI, Nov 8, 2021 /PRNewswire/ -- Novartis (China) and Philips (China) signed a Memorandum of Understanding on Strategic Cooperation at the 4th China International Import Expo, giving full play to their professional advantages in the field of medical health and medical artificial intelligence, taking the central nervous system demyelinating disease - multiple sclerosis as a breakthrough, by promoting the innovation of imaging technology, improving the diagnostic technology of multiple sclerosis, thereby further shortening the diagnosis cycle of rare diseases and improving the diagnosis rate.
Photo: Philips-Novartis signed a memorandum of understanding on strategic cooperation
<b>Wu Ling, Chief Scientific Officer and Head of Medical Affairs at Novartis Pharma China</b>, said: "Only by integrating the industry's most cutting-edge technology and rich experience can we develop better medical solutions for the benefit of patients. Novartis has been working in the field of central nervous system diseases for many years and has rich experience in disease diagnosis and management. This cooperation hopes to fully release the great potential brought by imaging technology innovation and artificial intelligence, accelerate the overcoming of the problems of "difficult to find" and "difficult to diagnose" rare diseases, and realize the beautiful vision of 'healthy China, no one can be less'. ”
Photo/ Philips-Novartis signing ceremony
<b>The clinical manifestations are complex and changeable, and the diagnosis cycle is long</b>
Multiple sclerosis (ms) is an immune-mediated disease characterized by inflammatory demyelinating lesions of the central nervous system, which was included in the "Catalogue of the First Rare Diseases in China" in 2018 According to the "2021 China Multiple Sclerosis Patient Survival Treatment Report", the time from the onset of the disease to the treatment of MS patients in China exceeds 1 year, the average diagnosis time is more than three years, and 50% of patients are misdiagnosed [1]ms Diagnosis and treatment can lead to serious disabilities such as paralysis and blindness. Accurate diagnosis, which causes a huge burden on families and society, and the early initiation of efficient treatment are important means to delay the progression of disability and reduce the disability rate.
Magnetic resonance imaging (MRI) is one of the keys to achieving early diagnosis of MS, and it is also of great value for follow-up and disease course evaluation.
Professor Liu Ya'ou, director of the Department of Radiology, Beijing Tiantan Hospital affiliated to Capital Medical University, said: "With the development of imaging technology, especially the development of mri technology, more subtle lesions can be found in the early stage of the disease, making our understanding of demyelinating diseases more comprehensive and in-depth, providing a strong basis for the follow-up treatment of clinicians However, in practical applications, there are still some challenges in imaging examination, such as insufficient standardization of research methods, lack of standardized tools and data, and uneven levels of inspectors. How to promote the standardization and customization of imaging examinations is what we urgently need to promote at present."
<b>With standardized clinical management as the center, we will jointly promote the whole course of disease image tracking diagnosis and treatment</b>
The cooperation between Novartis and Philips will include exploring the cooperation of specialized disease diagnosis and treatment management models centered on imaging diagnosis and standardized clinical management, jointly exploring and developing the possibility of advanced imaging diagnosis mode from multiple sclerosis diseases as a breakthrough, using cutting-edge medical imaging methods such as compression perception and artificial intelligence, driving customized and structured imaging reports, promoting the practice of diagnosis and treatment results of patients' full-course image tracking, shortening patients' diagnosis time and standardized clinical follow-up, and breaking through the boundaries of traditional diagnosis and treatment modes. Create disease-centric solutions and ecosystems that provide more scalable services to patients.
Liang Jianqiu, Vice President of Philips Greater China, General Manager of Total Solution Center and Head of Strategic Cooperation, said: "As a pioneer of digital innovation in the field of health care, Philips has always focused on the unmet clinical needs of China's medical system We believe that cooperation with Novartis can accelerate the application of cutting-edge technologies, one-stop solutions, innovative business models and other applications in the medical field, help MS patients shorten the diagnosis cycle, promote industry norms, and achieve greater value to the industry and patients."
[1] Blue Book of Health Insights for Multiple Sclerosis Patients in China and 2021 Report on the Quality of Life of Multiple Sclerosis Patients in China